Page 7 - அஜியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Sintra vai instalar novos contentores nas zonas balneares do concelho
greensavers.sapo.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greensavers.sapo.pt Daily Mail and Mail on Sunday newspapers.
O MIRANTE | Águas de Santarém investe 744 mil euros em estradas afectadas por obras da empresa
omirante.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from omirante.pt Daily Mail and Mail on Sunday newspapers.
Disclose All Assets Of Late Music Composer Wajid Khan â Bombay High Court To Mother, Brother Sajid Khan, On Widow s Testamentary Petition
Share This -
x
The Bombay High Court has sought a complete disclosure from the mother and brother of late Music composer Wajid Khan about all the assets owned by him, after his widow, Kamalrukh approached the HC in a testamentary petition against Sajid Khan and his mother Razia.
Wajid Sharafat Khan was a well-known music director in the Hindi film industry along with his elder brother Sajid Khan, working under the name of Sajid-Wajid for close to 20 years. Wajid was ailing since January, last year and eventually passed away on June 1, 2020, due to covid at a suburban hospital.
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ( Kazia , ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec s oncology project EVT801.
Message :
Required fields
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
2021-04-19 / 08:31
The issuer is solely responsible for the content of this announcement.
= . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
vimarsana © 2020. All Rights Reserved.